The phase II clinical trials data showed that INCB-13739 significantly improved insulin sensitivity in type 2 diabetic patients who failed in metformin treatment, and reduced the levels of triglyceride and cholesterol in hyperlipidemic patients [20,21]. This evidence concerns the gene INS and type 2 diabetes mellitus.